BR112023021803A2 - Composição farmacêutica compreendendo o composto smtp-7 - Google Patents
Composição farmacêutica compreendendo o composto smtp-7Info
- Publication number
- BR112023021803A2 BR112023021803A2 BR112023021803A BR112023021803A BR112023021803A2 BR 112023021803 A2 BR112023021803 A2 BR 112023021803A2 BR 112023021803 A BR112023021803 A BR 112023021803A BR 112023021803 A BR112023021803 A BR 112023021803A BR 112023021803 A2 BR112023021803 A2 BR 112023021803A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- smtp
- compound
- treatment
- additive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021070892 | 2021-04-20 | ||
| PCT/US2022/025462 WO2022226013A1 (en) | 2021-04-20 | 2022-04-20 | Pharmaceutical composition comprising the compound smtp-7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021803A2 true BR112023021803A2 (pt) | 2024-01-23 |
Family
ID=81648879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021803A BR112023021803A2 (pt) | 2021-04-20 | 2022-04-20 | Composição farmacêutica compreendendo o composto smtp-7 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240238252A1 (enExample) |
| EP (1) | EP4326258A1 (enExample) |
| JP (1) | JP2024525239A (enExample) |
| KR (1) | KR20230173129A (enExample) |
| CN (1) | CN117279634A (enExample) |
| AU (1) | AU2022262593A1 (enExample) |
| BR (1) | BR112023021803A2 (enExample) |
| CA (1) | CA3214630A1 (enExample) |
| WO (1) | WO2022226013A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026092761A1 (zh) * | 2024-11-04 | 2026-05-07 | 江苏恒瑞医药股份有限公司 | 包含smtp衍生物的药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4313049B2 (ja) | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| EP1944027A4 (en) | 2005-10-06 | 2009-08-19 | Univ Tokyo Nat Univ Corp | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEPHRITIS AND METHOD OF MANUFACTURE THEREOF |
| EP2604697B1 (en) | 2006-03-27 | 2015-07-01 | Tokyo University of Agriculture and Technology TLO | Triprenyl phenol compounds, process for their production and use as thrombolysis enhancer |
| ES2476041T3 (es) * | 2009-07-06 | 2014-07-11 | National University Corporation Tokyo University Of Agriculture And Technology | Agente citoprotector trifenilfen�lico |
| WO2011125930A1 (ja) | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
| AU2022275263A1 (en) * | 2021-05-10 | 2023-11-09 | Corxel Pharmaceuticals Hong Kong Limited | Pharmaceutical composition for use in treating cerebral infarction |
-
2022
- 2022-04-20 AU AU2022262593A patent/AU2022262593A1/en active Pending
- 2022-04-20 WO PCT/US2022/025462 patent/WO2022226013A1/en not_active Ceased
- 2022-04-20 CA CA3214630A patent/CA3214630A1/en active Pending
- 2022-04-20 US US18/287,489 patent/US20240238252A1/en active Pending
- 2022-04-20 CN CN202280033984.6A patent/CN117279634A/zh active Pending
- 2022-04-20 BR BR112023021803A patent/BR112023021803A2/pt unknown
- 2022-04-20 JP JP2023563075A patent/JP2024525239A/ja active Pending
- 2022-04-20 EP EP22723282.4A patent/EP4326258A1/en active Pending
- 2022-04-20 KR KR1020237038571A patent/KR20230173129A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4326258A1 (en) | 2024-02-28 |
| WO2022226013A1 (en) | 2022-10-27 |
| AU2022262593A1 (en) | 2023-11-02 |
| CN117279634A (zh) | 2023-12-22 |
| US20240238252A1 (en) | 2024-07-18 |
| KR20230173129A (ko) | 2023-12-26 |
| CA3214630A1 (en) | 2022-10-27 |
| JP2024525239A (ja) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| MX2022015613A (es) | Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. | |
| DOP2024000119A (es) | Composición farmacéutica que comprende un compuesto de quinazolina | |
| BR112022010323A2 (pt) | Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal | |
| BR112023000770A2 (pt) | Inibidor de egfr | |
| BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
| BR112022009861A2 (pt) | Derivado de cicloalquil ureia | |
| SA523450286B1 (ar) | مركب 4-أمينو كوينازولين | |
| BR112012025390B8 (pt) | Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto | |
| BR112017022101A2 (pt) | composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo | |
| DOP2022000110A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| BR112018070586A2 (pt) | compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos | |
| SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
| BR112021017314A2 (pt) | Uso de extrato de elaeocarpus sylvestris | |
| Fabry et al. | In-vitro activity of polyhexanide alone and in combination with antibiotics against Staphylococcus aureus | |
| Halpern et al. | Self-administered preoperative antiseptic wash to prevent postoperative infection after deep brain stimulation | |
| BR112014030325A8 (pt) | uso de composição contendo derivado de verbenona para a obtenção de produto destinado ao tratamento ou prevenção de doença cerebral degenerativa, alimento funcional para prevenir ou tratar doença neurodegenerativa e composto | |
| CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| BR112019025478A8 (pt) | Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer | |
| BR112023023534A2 (pt) | Composição farmacêutica para uso no tratamento de infarto cererbral | |
| BR112017016278A2 (pt) | agente preventivo e/ou terapêutico de doença imune | |
| BR112018004249A2 (pt) | composto, e, composição para prevenção ou tratamento de doenças trombóticas. | |
| BR112022020865A2 (pt) | Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo | |
| BR112014033088A2 (pt) | composição para prevenção ou tratamento de colite compreendendo s-alil-l-cisteína como ingrediente ativo, e preparação médica compreendendo a mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: JI XING PHARMACEUTICALS HONG KONG LIMITED (CN) |
|
| B25D | Requested change of name of applicant approved |
Owner name: CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) |